Eprazinone dihydrochloride

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Eprazinone 2HClide 是一种具有溶解粘液、溶解分泌物和支气管解痉作用的化合物。

Eprazinone 2hydrochloride is a drug with proposed mucolytic, secretolytic, and bronchial antispasmodic properties.(In Vitro):Eprazinone specifically displaces binding to the NK1R. Although Eprazinone displays a rather weak inhibition of [125I]BH-SP binding to NK1R, at a concentration of 25 μM, and an antagonistic effect of about 30%, NK1R blockade could contribute to its mucolytic activity.(In Vivo):Eprazinone (50-200 mg/kg; oral gavage; daily; for 4 days; adult male rats) at a dose of 200 mg/kg significantly increases total and individual (with the exception of phosphatidylinositol) phospholipid levels and decreases total neutral lipids. Lower doses of Eprazinone significantly decrease neutral lipid levels without affecting the phospholipids.In airway epithelial studies, mucosal addition of Eprazinone produces a dose-dependent partially reversible decrease in short-circuit current (Isc). The decrease in Isc at lower Eprazinone concentrations is accounted for entirely by a decrease in net chloride secretion while at higher concentrations both sodium and chloride transport are affected.

Eprazinone specifically displaces binding to the NK1R. Although Eprazinone displays a rather weak inhibition of [125I]BH-SP binding to NK1R, at a concentration of 25 μM, and an antagonistic effect of about 30%, NK1R blockade could contribute to its mucolytic activity.

Eprazinone (50-200 mg/kg; oral gavage; daily; for 4 days; adult male rats) at a dose of 200 mg/kg significantly increases total and individual (with the exception of phosphatidylinositol) phospholipid levels and decreases total neutral lipids. Lower doses of Eprazinone significantly decrease neutral lipid levels without affecting the phospholipids.In airway epithelial studies, mucosal addition of Eprazinone produces a dose-dependent partially reversible decrease in short-circuit current (Isc). The decrease in Isc at lower Eprazinone concentrations is accounted for entirely by a decrease in net chloride secretion while at higher concentrations both sodium and chloride transport are affected. Animal Model:Adult male pathogen free Fischer 344 inbred rats (200-250 g) Dosage:50 mg/kg, 100 mg/kg, and 200 mg/kg Administration:Oral gavage; daily; for 4 days Result:At a dose of 200 mg/kg significantly increased total and individual (with the exception of phosphatidylinositol) phospholipid levels and decreased total neutral lipids.

——

Others

Other Targets

Others

Other Indications

——

10402-53-6

453.44

C24H32N2O2·2HCl

>98% (HPLC)

Water: 18 mg/mL (39.69 mM); DMSO: 1 mg/mL (2.2 mM)

Cl.Cl.CCOC(CN1CCN(CC(C)C(=O)C2=CC=CC=C2)CC1)C1=CC=CC=C1

——

(-20℃)

With Ice Pack

≥ 2 years